Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

Author

S. Madhi

h-index 17 View on Semantic Scholar

We have 5 of 129 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

#protein folding Open access Oct 2026

Identifying candidate genetic determinants associated with invasion in pneumococcal lineages

This work conducted a species-wide genome-wide association study of invasion and compared the prevalence of significant unitigs in GPSC1 and GPSC21 to identify invasion-associated variants differentiating them, and highlighted candidate proteins that may help explain invasiveness and could be explored as vaccine antige...

M. Pesonen, O. Lorenz, M. du Plessis et al. · 0 citations
Open access Oct 2026

A phase III randomized study: Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine in healthy adults, adolescents, and children in India and healthy adolescents and children in South Africa.

BACKGROUND MenACYW-TT is a quadrivalent meningococcal conjugate vaccine approved for individuals aged ≥6 weeks. This Phase III study evaluated the immunogenicity and safety of a single dose of MenACYW-TT versus MenACYW-DT and MenPS-ACWY in healthy adults, adolescents, and children in India and in healthy adolescents an...

Ashish Bavdekar, D. Chansinghakul, Ravi Mandyam Dhati et al. · 0 citations
Sep 2026

Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial.

BACKGROUND Reduced-dosing pneumococcal conjugate vaccine (PCV) schedules (single primary dose plus booster [1+1]) are being considered and have been deployed in the UK. We aimed to evaluate the persistence of serotype-specific immunity until age 5 years in infants randomly assigned to 1+1 or two primary doses plus boos...

Daniel Kapelus, C. Olwagen, A. Izu et al. · 0 citations
Review Open access Sep 2026

Clesrovimab, a monoclonal antibody for the prevention of respiratory syncytial virus disease in infants: a drug profile.

INTRODUCTION Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection (LRTI) in young children. In children < 5 years old, it causes an estimated 33 million LRTI episodes and over 100,000 deaths annually, two-thirds of which occur in infants. The licensure of new long-acting monoc...

M. Wiedenmann, Z. Dangor, S. Madhi · 0 citations
Open access Sep 2026

An integrative computational and experimental evaluation of natural compounds with potential to target LuxS in Klebsiella pneumoniae

Findings identify resveratrol as a promising anti-virulence candidate and highlight the utility of integrative computational and experimental strategies for the identification of compounds targeting quorum sensing and biofilm formation inhibition in multidrug-resistant pathogens.

Mashego Jackson Mamosebo, Suheena Ayrga, S. Madhi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.